Technology Offerings

Purin-Ago: New Non-Nucleotide Agonists for P2Y11 Receptor

Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide

agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Comments (0)

Write a comment